• +1-646-491-9876
    • +91-20-67278686

    Search

    Memory Impairment - Pipeline Review, H1 2015

    Memory Impairment - Pipeline Review, H1 2015

    • Report Code ID: RW0001172414
    • Category Pharmaceuticals
    • No. of Pages 70
    • Publication Month Jan-15
    • Publisher Name Global Markets Direct
    Memory Impairment-Pipeline Review, H1 2015

    Summary

    Publisher's, 'Memory Impairment-Pipeline Review, H1 2015', provides an overview of the Memory Impairment's therapeutic pipeline.

    This report provides comprehensive information on the therapeutic development for Memory Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Memory Impairment and special features on late-stage and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

    The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

    Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

    Scope

    - The report provides a snapshot of the global therapeutic landscape of Memory Impairment
    - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in the therapeutics development for Memory Impairment and enlists all their major and minor projects
    - The report summarizes all the dormant and discontinued pipeline projects
    - A review of the Memory Impairment products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - A detailed assessment of monotherapy and combination therapy pipeline projects
    - Coverage of the Memory Impairment pipeline on the basis of target, MoA, route of administration and molecule type
    - Latest news and deals relating related to pipeline products

    Reasons to buy

    - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Identify and understand important and diverse types of therapeutics under development for Memory Impairment
    - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
    - Devise corrective measures for pipeline projects by understanding Memory Impairment pipeline depth and focus of Indication therapeutics
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    Table of Contents
    Table of Contents 2
    List of Tables 5
    List of Figures 5
    Introduction 7
    Global Markets Direct Report Coverage 7
    Memory Impairment Overview 8
    Therapeutics Development 9
    Pipeline Products for Memory Impairment-Overview 9
    Pipeline Products for Memory Impairment-Comparative Analysis 10
    Memory Impairment-Therapeutics under Development by Companies 11
    Memory Impairment-Therapeutics under Investigation by Universities/Institutes 12
    Memory Impairment-Pipeline Products Glance 13
    Clinical Stage Products 13
    Early Stage Products 14
    Memory Impairment-Products under Development by Companies 15
    Memory Impairment-Products under Investigation by Universities/Institutes 17
    Memory Impairment-Companies Involved in Therapeutics Development 18
    Calico LLC 18
    Dart NeuroScience LLC 19
    M et P Pharma AG 20
    Neuren Pharmaceuticals Limited 21
    Omeros Corporation 22
    Pharnext SAS 23
    Sunovion Pharmaceuticals Inc. 24
    Takeda Pharmaceutical Company Limited 25
    Memory Impairment-Therapeutics Assessment 26
    Assessment by Monotherapy Products 26
    Assessment by Target 27
    Assessment by Mechanism of Action 29
    Assessment by Route of Administration 31
    Assessment by Molecule Type 33
    Drug Profiles 35
    2-PMPA-Drug Profile 35
    Product Description 35
    Mechanism of Action 35
    R&D Progress 35
    AC-253-Drug Profile 36
    Product Description 36
    Mechanism of Action 36
    R&D Progress 36
    Antisense Oligonucleotide to Inhibit microRNA for Neurology-Drug Profile 37
    Product Description 37
    Mechanism of Action 37
    R&D Progress 37
    dehydroevodiamine hydrochloride-Drug Profile 38
    Product Description 38
    Mechanism of Action 38
    R&D Progress 38
    Drug for Memory Impairment-Drug Profile 39
    Product Description 39
    Mechanism of Action 39
    R&D Progress 39
    HT-0712-Drug Profile 40
    Product Description 40
    Mechanism of Action 40
    R&D Progress 40
    HT-3951-Drug Profile 41
    Product Description 41
    Mechanism of Action 41
    R&D Progress 41
    NNZ-2591-Drug Profile 42
    Product Description 42
    Mechanism of Action 42
    R&D Progress 42
    P7-C3A20-Drug Profile 44
    Product Description 44
    Mechanism of Action 44
    R&D Progress 44
    pregnenolone succinate-Drug Profile 46
    Product Description 46
    Mechanism of Action 46
    R&D Progress 46
    PXT-864-Drug Profile 47
    Product Description 47
    Mechanism of Action 47
    R&D Progress 47
    roflumilast-Drug Profile 48
    Product Description 48
    Mechanism of Action 48
    R&D Progress 48
    Small Molecule 1 to Inhibit GlyT-1 for Memory Impairment-Drug Profile 51
    Product Description 51
    Mechanism of Action 51
    R&D Progress 51
    Small Molecule 1 to Inhibit PDE4 for Memory Impairment-Drug Profile 52
    Product Description 52
    Mechanism of Action 52
    R&D Progress 52
    Small Molecule 2 to Inhibit Glyt-1 for Memory Impairment-Drug Profile 53
    Product Description 53
    Mechanism of Action 53
    R&D Progress 53
    Small Molecule 2 to Inhibit PDE4 for Memory Impairment-Drug Profile 54
    Product Description 54
    Mechanism of Action 54
    R&D Progress 54
    Small Molecule to Activate LPL for CNS and Metabolic Disorders-Drug Profile 55
    Product Description 55
    Mechanism of Action 55
    R&D Progress 55
    Small Molecule to Inhibit D-amino acid oxidase for Neuropathic Pain, Inflammatory Pain and Memory Impairment-Drug Profile 56
    Product Description 56
    Mechanism of Action 56
    R&D Progress 56
    Small Molecule to Inhibit MAO-B for Memory Impairment-Drug Profile 57
    Product Description 57
    Mechanism of Action 57
    R&D Progress 57
    Small Molecule to Target GPR83 for CNS and Immunological Disorders-Drug Profile 58
    Product Description 58
    Mechanism of Action 58
    R&D Progress 58
    Small Molecules to Activate Carbonic Anhydrase for Learning and Memory Impairment-Drug Profile 59
    Product Description 59
    Mechanism of Action 59
    R&D Progress 59
    Small Molecules to Activate NAMPT for Neurological Disorders-Drug Profile 60
    Product Description 60
    Mechanism of Action 60
    R&D Progress 60
    Small Molecules to Activate PKC for CNS and Oncology-Drug Profile 61
    Product Description 61
    Mechanism of Action 61
    R&D Progress 61
    Small Molecules to Antagonize GALR3 for Memory Impairment-Drug Profile 62
    Product Description 62
    Mechanism of Action 62
    R&D Progress 62
    Stem Cell Therapy for Memory Impairment and Brain Diseases-Drug Profile 63
    Product Description 63
    Mechanism of Action 63
    R&D Progress 63
    Memory Impairment-Recent Pipeline Updates 64
    Memory Impairment-Dormant Projects 67
    Appendix 69
    Methodology 69
    Coverage 69
    Secondary Research 69
    Primary Research 69
    Expert Panel Validation 69
    Contact Us 69
    Disclaimer 70

    List of Tables
    Number of Products under Development for Memory Impairment, H1 2015 9
    Number of Products under Development for Memory Impairment-Comparative Analysis, H1 2015 10
    Number of Products under Development by Companies, H1 2015 11
    Number of Products under Investigation by Universities/Institutes, H1 2015 12
    Comparative Analysis by Clinical Stage Development, H1 2015 13
    Comparative Analysis by Early Stage Development, H1 2015 14
    Products under Development by Companies, H1 2015 15
    Products under Development by Companies, H1 2015 (Contd..1) 16
    Products under Investigation by Universities/Institutes, H1 2015 17
    Memory Impairment-Pipeline by Calico LLC, H1 2015 18
    Memory Impairment-Pipeline by Dart NeuroScience LLC, H1 2015 19
    Memory Impairment-Pipeline by M et P Pharma AG, H1 2015 20
    Memory Impairment-Pipeline by Neuren Pharmaceuticals Limited, H1 2015 21
    Memory Impairment-Pipeline by Omeros Corporation, H1 2015 22
    Memory Impairment-Pipeline by Pharnext SAS, H1 2015 23
    Memory Impairment-Pipeline by Sunovion Pharmaceuticals Inc., H1 2015 24
    Memory Impairment-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 25
    Assessment by Monotherapy Products, H1 2015 26
    Number of Products by Stage and Target, H1 2015 28
    Number of Products by Stage and Mechanism of Action, H1 2015 30
    Number of Products by Stage and Route of Administration, H1 2015 32
    Number of Products by Stage and Molecule Type, H1 2015 34
    Memory Impairment Therapeutics-Recent Pipeline Updates, H1 2015 64
    Memory Impairment-Dormant Projects, H1 2015 67
    Memory Impairment-Dormant Projects (Contd..1), H1 2015 68

    List of Figures
    Number of Products under Development for Memory Impairment, H1 2015 9
    Number of Products under Development for Memory Impairment-Comparative Analysis, H1 2015 10
    Number of Products under Development by Companies, H1 2015 11
    Number of Products under Investigation by Universities/Institutes, H1 2015 12
    Comparative Analysis by Clinical Stage Development, H1 2015 13
    Comparative Analysis by Early Stage Products, H1 2015 14
    Assessment by Monotherapy Products, H1 2015 26
    Number of Products by Top 10 Targets, H1 2015 27
    Number of Products by Stage and Top 10 Targets, H1 2015 27
    Number of Products by Top 10 Mechanism of Actions, H1 2015 29
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 29
    Number of Products by Top 10 Routes of Administration, H1 2015 31
    Number of Products by Stage and Top 10 Routes of Administration, H1 2015 32
    Number of Products by Top 10 Molecule Types, H1 2015 33
    Number of Products by Stage and Top 10 Molecule Types, H1 2015 34
    Calico LLC
    Dart NeuroScience LLC
    M et P Pharma AG
    Neuren Pharmaceuticals Limited
    Omeros Corporation
    Pharnext SAS
    Sunovion Pharmaceuticals Inc.
    Takeda Pharmaceutical Company Limited

    Request for Sample

    Report Url https://www.reportsweb.com//memory-impairment-pipeline-review-h1-2015&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//memory-impairment-pipeline-review-h1-2015&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//memory-impairment-pipeline-review-h1-2015&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments